BTIG downgraded Zosano Pharma from Buy to Neutral

Maxim Group reiterated coverage of Zosano Pharma with a rating of Buy and set a new price target of $2.50 from $1.50 previously

SC 13G - Zosano Pharma Corp (0001587221) (Subject)

FREMONT, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced changes to its board of directors, including the appointment of Elaine M. Yang. "We are pleased to welcome Elaine, a high caliber executive, to our board of directors," said Steven Lo, president and chief executive officer of Zosano. "Elaine has deep and broad executive leadership experience, building and running cross functional departments, including business operations functions for companies with fast growth trajectories such as Genentech and Facebook, and her experience will be valuable to Zosano as we plan for success." Elaine M

FREMONT, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the appointment of Kathy McGee, an accomplished biopharmaceutical executive, to its board of directors. Ms. McGee brings experience from a broad range of leadership roles across operations, strategic planning, manufacturing and supply chain management, quality and regulatory affairs and new product development. "Kathy is an exceptional addition to the board, bringing deep experience across many functional areas, and we are thrilled to have her join our board," said Steven Lo, president and chief executive officer of Zosano. "As we work to

4 - Zosano Pharma Corp (0001587221) (Issuer)

4 - Zosano Pharma Corp (0001587221) (Issuer)

4 - Zosano Pharma Corp (0001587221) (Issuer)

4 - Zosano Pharma Corp (0001587221) (Issuer)

4 - Zosano Pharma Corp (0001587221) (Issuer)

4 - Zosano Pharma Corp (0001587221) (Issuer)

3 - Zosano Pharma Corp (0001587221) (Issuer)

4 - Zosano Pharma Corp (0001587221) (Issuer)

4 - Zosano Pharma Corp (0001587221) (Issuer)

4 - Zosano Pharma Corp (0001587221) (Issuer)

25-NSE - Zosano Pharma Corp (0001587221) (Subject)

8-K - Zosano Pharma Corp (0001587221) (Filer)

8-K - Zosano Pharma Corp (0001587221) (Filer)

8-K - Zosano Pharma Corp (0001587221) (Filer)

10-Q - Zosano Pharma Corp (0001587221) (Filer)

8-K - Zosano Pharma Corp (0001587221) (Filer)

8-K - Zosano Pharma Corp (0001587221) (Filer)

10-K/A - Zosano Pharma Corp (0001587221) (Filer)

8-K - Zosano Pharma Corp (0001587221) (Filer)

S-8 - Zosano Pharma Corp (0001587221) (Filer)

FREMONT, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that on June 1, 2022 it filed a voluntary petition for relief under chapter 11 of title 11 ("Chapter 11") of the United States Bankruptcy Code (the "Bankruptcy Code") in the United States Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"), thereby commencing a Chapter 11 case for the company. Zosano continues to operate its business as a "debtor-in-possession" under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and orders of the Bankruptcy Court. Zosano

PRESS RELEASE Emergex Vaccines Announces the Successful Coating of its Novel CD8+ T cell Adaptive COVID-19 Vaccine onto Zosano Pharma's Micro-Needle Patch Emergex's COVID-19 and Dengue CD8+ T cell Adaptive vaccines are already in clinical trials Abingdon, Oxon, UK, 17th May 2022 – Emergex Vaccines Holding Limited (‘Emergex', or the ‘Company'), a clinical stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, today announced that its COVID-19 vaccine candidate has been successfully coated onto Zosano Pharma Corporation's (NASDAQ:ZSAN) proprietary microneedle patch system. Zosano's patch consists of

FREMONT, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2022. All share and per share information included in these financial results and statements has been retroactively adjusted to give effect to our April 11, 2022 1-for-35 reverse stock split. Zosano reported a net loss for the first quarter of 2022 of $33.4 million, or $7.86 per share on a basic and diluted basis, compared with a net loss of $8.1 million, or $2.73 per share on a basic and diluted basis, for the same quarter in 2021. Research and development expenses for the first quar

FREMONT, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today provided a corporate update. On April 14, 2022, the Food and Drug Administration granted Zosano a twelve-month extension to April 20, 2023 to resubmit its M207 New Drug Application. However, in order to preserve its capital and cash resources, Zosano has suspended its M207 program. Additionally, the company's remaining feasibility study with a pharmaceutical partner is expected to conclude this quarter. Zosano recently implemented an additional workforce reduction impacting approximately 40% of its remaining employees and suspended GMP manufacturi

FREMONT, Calif., April 11, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its Board of Directors has approved a 1-for-35 reverse stock split of the company's common stock. The reverse stock split will become effective today, April 11, 2022. The company's common stock is expected to begin trading on a split-adjusted basis when the markets open on April 12, 2022 under the existing trading symbol "ZSAN." The reverse stock split is primarily intended to bring the company into compliance with the minimum bid price requirements for maintaining its listing on the Nasdaq Capital Market. The new CUSIP num

FREMONT, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2021, as well as business updates. "We are in discussions with the FDA to determine if there is a viable option to pursue approval of M207 using the currently available clinical data. In addition, we are actively evaluating financial and strategic alternatives in collaboration with external advisors, with a goal of maximizing value," said Steven Lo, president and chief executive officer of Zosano. "We believe our proprietary transdermal microneedle patch technology offer

FREMONT, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 51,250,000 units, each consisting of one share of common stock and one warrant to purchase one share of common stock, at a public offering price of $0.30 per unit. The warrants have an exercise price of $0.30 per share, are immediately exercisable and will expire five years from the date of issuance. Zosano has granted the underwriter a 30-day option to purchase up to an additional 7,687,500 shares of common stock and/or additional warrants to purchase up to 7,687,500 s

FREMONT, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it is commencing an underwritten public offering of units consisting of shares of common stock and warrants to purchase common stock. All of the units in the offering are to be sold by Zosano. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Maxim Group LLC is acting as the sole book-running manager for the proposed offering. A registration statement relating to these securities has been filed with th

FREMONT, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the publication of Phase 1 clinical trial data in an article titled, "Immunogenicity and Safety of Inactivated Influenza Split-Virion Vaccine Administered via a Transdermal Microneedle System" in the Journal of Vaccines and Immunology. The data demonstrated that a low dose of a trivalent influenza vaccine administered via its transdermal microneedle system produced antibody levels that met EMEA's three guidelines for influenza vaccine efficacy and was generally well tolerated. "We are excited to report these results, which show that a lowe

FREMONT, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced changes to its board of directors, including the appointment of Elaine M. Yang. "We are pleased to welcome Elaine, a high caliber executive, to our board of directors," said Steven Lo, president and chief executive officer of Zosano. "Elaine has deep and broad executive leadership experience, building and running cross functional departments, including business operations functions for companies with fast growth trajectories such as Genentech and Facebook, and her experience will be valuable to Zosano as we plan for success." Elaine M

Gainers bluebird bio (NASDAQ:BLUE) shares rose 53.4% to $6.12 during Friday's after-market session. Trading volume for this security closed at 5.0 million, accounting for 206.3% of its average full-day volume over the last 100 days. The company's market cap stands at $437.2 million. Aileron Therapeutics (NASDAQ:ALRN) stock moved upwards by 27.46% to $0.53. The company's market cap stands at $48.1 million. ABVC BioPharma (NASDAQ:ABVC) shares moved upwards by 20.0% to $1.08. The company's market cap stands at $34.8 million. Lixte Biotech Hldgs (NASDAQ:LIXT) shares increased by 10.22% to $0.83. The market value of their outstanding shares is at $13.8 million. Minerva Neurosciences (NASDAQ:

Gainers Helbiz, Inc. (NASDAQ:HLBZ) shares rose 38% to $1.27 in pre-market trading following a Form 4 filing showing the purchase of 2,044,676 shares by CEO Salvatore Palella at an average price of $0.99. BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) rose 34.4% to $6.99 in pre-market trading after declining over 5% on Monday. Cemtrex, Inc. (NASDAQ:CETX) rose 22.8% to $0.3701 in pre-market trading. Kohl's Corporation (NYSE:KSS) rose 12.7% to $47.50 in pre-market trading after Franchise Group confirmed it was in exclusive negotiations for three weeks to acquire the company for $60 per share in cash. GitLab Inc. (NASDAQ:GTLB) rose 12% to $44.60 in pre-market trading following better-tha

Gainers AeroClean Technologies, Inc. (NASDAQ:AERC) shares gained 100.4% to close at $4.75 on Monday after the FDA granted clearance for the company's pūrgo technology, classifying it as a class II medical device. Yumanity Therapeutics, Inc. (NASDAQ:YMTX) jumped 40.1% to close at $1.99 after the company announced definitive agreements for two strategic transactions. Assure Holdings Corp. (NASDAQ:IONM) gained 37.9% to settle at $2.40. Pineapple Energy Inc. (NASDAQ:PEGY) shares climbed 35.5% to settle at $3.17. Pineapple Holdings, last month, posted a Q1 loss of $0.58 per share. Cerberus Cyber Sentinel Corporation (NASDAQ:CISO) climbed 32.2% to close at $9.00. FTC Solar, Inc. (NASDAQ:F

Gainers Vaxxinity (NASDAQ:VAXX) stock moved upwards by 10.2% to $3.56 during Monday's after-market session. The company's market cap stands at $448.5 million. Delcath Systems (NASDAQ:DCTH) shares increased by 9.77% to $4.94. Trading volume for this security closed at 97.8K, accounting for 386.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $39.0 million. Adicet Bio (NASDAQ:ACET) shares increased by 8.38% to $13.29. The company's market cap stands at $531.5 million. First Wave BioPharma (NASDAQ:FWBI) stock increased by 6.72% to $0.31. The company's market cap stands at $6.6 million. Recursion Pharmaceuticals (NASDAQ:RXRX) share

Gainers DiDi Global Inc. (NYSE:DIDI) jumped 51.4% to $2.80 after the Chinese government said the company can resume adding new users. Yumanity Therapeutics, Inc. (NASDAQ:YMTX) gained 36.5% to $1.9384 after the company announced definitive agreements for two strategic transactions. Pineapple Energy Inc. (NASDAQ:PEGY) shares jumped 34.6% to $3.15. Pineapple Holdings, last month, posted a Q1 loss of $0.58 per share. The Arena Group Holdings, Inc. (NYSE:AREN) gained 25.5% to $13.42. Futu Holdings Limited (NASDAQ:FUTU) surged 25.3% to $46.19 after the company reported Q1 earnings results. Cerberus Cyber Sentinel Corporation (NASDAQ:CISO) jumped 24.5% to $8.48. Kanzhun Limited (NASDAQ

Gainers Turning Point Therapeutics, Inc. (NASDAQ:TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share. Energy Focus, Inc. (NASDAQ:EFOI) shares gained 48.7% to settle at $1.65 after declining around 9% on Thursday. Galecto, Inc. (NASDAQ:GLTO) jumped 35.2% to settle at $1.96. Yumanity Therapeutics, Inc. (NASDAQ:YMTX) gained 34% to close at $1.42. Yumanity Therapeutics, last month, posted a Q1 loss of $1.24 per share. Houston American Energy Corp. (NYSE:HUSA) climbed 27.5% to close at $5.65. Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) climbed 26.4% to close at $12.35 after the company

  Gainers Turning Point (NASDAQ:TPTX) shares rose 116.6% to $74.0 during Friday's regular session. As of 13:30 EST, Turning Point's stock is trading at a volume of 22.4 million, which is 3412.5% of its average full-day volume over the last 100 days. The company's market cap stands at $3.6 billion. Curis (NASDAQ:CRIS) stock increased by 27.28% to $1.03. As of 13:30 EST, this security is trading at a volume of 8.8 million shares, making up 360.3% of its average full-day volume over the last 100 days. The company's market cap stands at $94.4 million. Avalo Therapeutics (NASDAQ:AVTX) stock increased by 25.4% to $0.39. The current volume of 1.6 million shares is 387.9% of Avalo Therapeutics

 Gainers Turning Point Therapeutics, Inc. (NASDAQ:TPTX) shares jumped 115.8% to $73.72 after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share. Energy Focus, Inc. (NASDAQ:EFOI) shares jumped 32.8% to $1.4740 after declining around 9% on Thursday. Nutex Health, Inc. (NASDAQ:NUTX) gained 20.6% to $11.11. Sprague Resources LP (NYSE:SRLP) shares jumped 19.8% to $18.96 after the company announced an agreement to be acquired by Hartree Partners for $19 per common unit. Kubient, Inc. (NASDAQ:KBNT) gained 19.5% to $1.19. Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) gained 18.9% to $11.62 after the company announced the FDA extended the review timeline

Gainers The Marygold Companies, Inc. (NYSE:MGLD) rose 38.8% to $2.04 in pre-market trading. Marygold Companies, last month, posted Q1 earnings of $0.02 per share. Energy Focus, Inc. (NASDAQ:EFOI) shares rose 21.5% to $1.35 in pre-market trading after declining around 9% on Thursday. Okta, Inc. (NASDAQ:OKTA) rose 15.7% to $108.45 in pre-market trading after the company reported better-than-expected Q1 sales results. The company also issued Q2 sales guidance above analyst estimates. StoneCo Ltd. (NASDAQ:STNE) rose 15.2% to $12.00 in pre-market trading after the company reported first-quarter revenue growth of 138.6% year-over-year to R$2.07 billion, above the mid-range of the company’s

Gainers NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) shares gained 47.5% to settle at $0.8436 on Thursday. Based on the review of approximately 460 patients, Data Safety and Monitoring Board (DSMB) recently determined that the evaluation of NRx Pharmaceuticals’ Zyesami (aviptadil) should cease due to futility. Repare Therapeutics Inc. (NASDAQ:RPTX) surged 44.8% to close at $12.67 on Thursday after the company announced it has entered into a worldwide license and collaboration agreement with Roche for the development and commercialization of camonsertib. Repare will receive a $125 million upfront payment and is eligible to receive up to an additional $1.2 billion in potential milestones. Talk